If you've been experiencing constipation symptoms, or if you've already been diagnosed with chronic constipation, you may not have found a treatment that works. This page discusses how AMITIZA can help and how it works differently than the laxatives or fiber you may have tried before. And when you're ready, talk to your doctor about a treatment plan.
Since there are different types of chronic constipation, your doctor will prescribe a medicine for your specific condition. AMITIZA is the first and only FDA-approved prescription medication for the treatment of Chronic Idiopathic Constipation (CIC) in adults, Irritable Bowel Syndrome with Constipation (IBS-C) in adult women, and Opioid-Induced Constipation (OIC) in adults with chronic, non-cancer pain.
Take a look at the results from the CIC clinical studies below to see how AMITIZA has helped other patients.
In two 4-week clinical studies:
AMITIZA (24 mcg) twice daily is approved to treat Chronic Idiopathic Constipation in adults. If you have CIC, AMITIZA may help you find the relief you're looking for.
Individual results may vary.
When people diagnosed with Irritable Bowel Syndrome also experience frequent constipation, it is known as Irritable Bowel Syndrome with Constipation, or IBS-C. Learn more about these clinical studies below.
In 2 different clinical studies, AMITIZA improved the overall symptoms of IBS-C in adult women which includes:
AMITIZA (8 mcg) twice daily is an approved prescription treatment for IBS-C in women 18 years of age and older. If your doctor diagnoses you with IBS-C, AMITIZA may be able to help.
Individual results may vary.
People taking opioids, a commonly prescribed pain reliever, can develop constipation as a side effect. This is referred to as Opioid-Induced Constipation, or OIC. The effects of AMITIZA in patients with OIC were evaluated in 3 clinical studies. See results from these 3 studies below.
AMITIZA was evaluated in 3 12-week clinical studies. Patients were taking opioid therapy for chronic, non-cancer pain, and experiencing symptoms of OIC.
Comparing patients taking AMITIZA (24 mcg twice daily) to patients taking a placebo, more AMITIZA patients experienced an overall spontaneous bowel movement response
Studies 2 and 3
Measuring the difference in spontaneous bowel movement frequency over an 8-week period between patients taking AMITIZA (24 mcg twice daily) vs patients taking a placebo:
The effectiveness of AMITIZA has not been established if you are taking a diphenylheptane opioid (e.g., methadone).
AMITIZA (24 mcg) twice daily is approved to treat constipation caused by opioids in adults with chronic, non-cancer pain. If you have OIC and chronic, non-cancer pain, AMITIZA may be able to help.
Individual results may vary.
AMITIZA isn’t a fiber or a laxative and it works differently than the laxative treatments you may have tried.
Chloride channels regulate fluid balance, a key factor in your body’s ability to pass stool. AMITIZA works locally in the intestines to activate these chloride channels, which helps:
The way AMITIZA works for IBS-C is not fully understood.
Sharing your history with chronic constipation helps your doctor find the treatment plan that is right for you. The Doctor Discussion Guide can help make the conversation more productive.
Find out what to expect when taking AMITIZA.
AMITIZA is for CIC in adults, OIC in adults with chronic, non-cancer pain, and IBS-C in women ≥ 18 years. Effectiveness in patients taking methadone has not been established.
AMITIZA (lubiprostone) is not for everyone. If you know or suspect you have a bowel blockage, do not take AMITIZA. If you are unsure, your healthcare provider (HCP) should evaluate your condition before starting AMITIZA. You should not take AMITIZA if you have severe diarrhea.
Some patients taking AMITIZA may experience nausea or diarrhea. If nausea occurs, take AMITIZA with food and water, if it becomes severe, tell your HCP. If your diarrhea becomes severe, stop taking AMITIZA and tell your HCP.
Within an hour of taking AMITIZA, a sensation of chest tightness and shortness of breath may occur. These symptoms usually go away within three hours, but may recur with repeated use. Tell your HCP if you experience these symptoms.
The most common side effects of taking AMITIZA (24 mcg) twice daily are nausea, diarrhea, headache, abdominal pain, abdominal distension, and gas for patients treated for CIC; nausea and diarrhea for patients treated for Opioid-Induced Constipation. The most common side effects of taking AMITIZA (8 mcg) twice daily for IBS-C are nausea, diarrhea, and abdominal pain. These are not all the side effects associated with AMITIZA.
Tell your HCP if you are taking a diphenylheptane opioid (e.g. methadone).
AMITIZA has not been studied in pregnant women. Based on animal studies, AMITIZA may cause fetal harm. AMITIZA should only be used during pregnancy if the potential benefits justify the potential risk to the fetus. If you are pregnant or become pregnant while being treated with AMITIZA, talk to your HCP to evaluate the risks to the fetus. Tell your HCP if you are nursing and monitor infants for diarrhea.
Tell your HCP if you have liver problems.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call
AMITIZA (lubiprostone) 24 mcg capsules twice daily is approved to treat Chronic Idiopathic Constipation (CIC) in adults. “Idiopathic” means the cause of the constipation is unknown and not due to an underlying illness or medication. AMITIZA 24 mcg twice daily is also approved to treat constipation caused by opioids (OIC), a type of prescription pain medicine, in adults with chronic, non-cancer pain. The effectiveness of AMITIZA has not been established if you are taking a diphenylheptane opioid (e.g., methadone). AMITIZA 8 mcg capsules twice daily is approved to treat Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years of age and older.
Please click here for complete Prescribing Information.
You are about to leave this website and enter a website operated by an independent third party.
The links to third-party websites contained on this website are provided solely for your convenience. Takeda does not control the content contained on any third-party website linked from this website. Your activities on those websites will be governed by the policies and practices of those third parties.
Please select "Continue" if you wish to be taken to this third-party website.
This offer cannot be used if you are a beneficiary of, or any part of your prescription is covered by:
You must meet Eligibility Requirements. You agree to report your use of this offer to any Third Party that reimburses you or pays for any part of the prescription price. Use of this offer is confirmation that you are permitted, under the terms and conditions of the health benefit plan(s) covering your prescriptions, to take advantage of co-pay coverage programs. You additionally agree that you will not submit the cost of any portion of the product dispensed pursuant to this offer to a federal or state healthcare program for purposes of counting it toward your out-of-pocket expenses. This savings card covers out-of-pocket expenses up to a maximum benefit of $75 for a 30-day prescription or up to $225 for a 90-day prescription. For mail order prescriptions, a mail-in rebate form is available at www.patientrebateonline.com or by calling 1-866-279-8995. This coupon is not valid with any other program, discount, or incentive involving AMITIZA (lubiprostone). Offer expires 03/31/2017. This offer may be rescinded, revoked, or amended without notice. No reproductions. This offer is void where prohibited by law, taxed, or restricted. Limit one offer per purchase. Cash value of 1/100 of 1¢. For questions about this offer, call the Customer Service Center at
We are unable to complete your web registration. Please contact 1-866-279-8995 to activate a Savings Card.